Biotech Values

[vinmantoo]

I'm not looking to defend the report since I disagree with conclusions

Mouton29, I wasn't inferring that you believed their conclusions or supported them. I was just mocking the end predictions.

These reports are often laughable. The one accompanying the ENTA downgrade (provided by jbog) was written by someone who seems clueless.

Enanta downgraded to Underweight from Neutral at JPMorgan 06:25
ENTA
JPMorgan downgraded Enanta to Underweight from Neutral with a $14 price target. The analyst sees an "undifferentiated" efficacy profile for EDP-235 post the Phase 2 SPRINT readout, and with pivotal development for the asset subject to partnership, a challenging path ahead for the candidate in COVID-19. Moreover, independent of partnership, there are several hurdles to both successful trial execution and detection of clinical benefit with a direct antiviral in a post-COVID exposed setting, with a commercial launch likely a 2027 or beyond event,

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172554515

How in the world can he/she say EDP-235 showed an undifferentiated efficacy profile? EDP-235 showed a statistically significant reduction in symptoms in a low risk population, something Paxlovid failed to do. That improvement was seen even though some 90% of the treated patients in SPRINT had previously had Covid. That seems like a key differentiating factor to me.